{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T16:46:01Z","timestamp":1789922761574,"version":"4.0.1"},"reference-count":20,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2005,12,9]],"date-time":"2005-12-09T00:00:00Z","timestamp":1134086400000},"content-version":"vor","delay-in-days":5731,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[1990,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A 6\u2010month double\u2010blind, parallel, randomized, placebo\u2010controlled multicenter trial of auranofin (0.15\u20130.20 mg\/kg\/day) was conducted in 231 children with juvenile rheumatoid arthritis (JRA) in the United States and in the Union of Soviet Socialist Republics. Approximately 80% of the children had polyarticular disease. The auranofin\u2010treated patients showed greater mean decreases from baseline in 11 of the 12 articular disease indices measured than did the placebo\u2010treated subjects after 3 months of therapy, and in 9 of the 12 indices after 6 months. However, the actual intergroup mean differences were relatively small and were not statistically significant. According to the physician's global assessment, 69% of the auranofin\u2010treated patients and 61% of the placebo\u2010treated patients demonstrated clinically significant improvement from baseline after 6 months (<jats:italic>P<\/jats:italic> = 0.24). Children whose disease onset occurred less than 2 years prior to entry improved more than did those who had arthritis for a longer period. In addition, those with polyarticular involvement at baseline improved more than did patients with mild disease. However, these relationships were observed in both the auranofin\u2010 and placebo\u2010treated groups, and again, there were no significant intergroup differences. Diarrhea was the most common adverse effect of auranofin. We conclude that the clinical efficacy of auranofin is modestly higher than that of placebo in the treatment of JRA, as evidenced by the consistent trends observed in the data. However, the magnitude of the individual intergroup differences is not statistically significant. Auranofin appears to be very safe in children with JRA.<\/jats:p>","DOI":"10.1002\/art.1780330402","type":"journal-article","created":{"date-parts":[[2007,2,14]],"date-time":"2007-02-14T23:29:27Z","timestamp":1171495767000},"page":"466-476","source":"Crossref","is-referenced-by-count":59,"title":["Auranofin in the treatment of juvenile rheumatoid arthritis"],"prefix":"10.1002","volume":"33","author":[{"given":"Edward H.","family":"Giannini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Earl J.","family":"Brewer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Kuzmina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandr","family":"Shaikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Wallin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,12,9]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198605153142001"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310103"},{"key":"e_1_2_1_4_2","first-page":"695","article-title":"An analysis of worldwide safety experience with auranofin","volume":"12","author":"Heuer MA","year":"1985","journal-title":"J Rheumatol"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780261102"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(83)90484-9"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-0172(84)90029-5"},{"key":"e_1_2_1_8_2","first-page":"496","article-title":"Blood and serum concentrations of gold after a single dose of auranofin in children with juvenile rheumatoid arthritis","volume":"10","author":"Giannini EH","year":"1983","journal-title":"J Rheumatol"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.43.2.228"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(83)80312-6"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(83)90490-4"},{"key":"e_1_2_1_12_2","first-page":"768","article-title":"Long\u2010term auranofin therapy in patients with juvenile rheumatoid arthritis","volume":"13","author":"Giannini EH","year":"1986","journal-title":"J Rheumatol"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310806"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780230903"},{"issue":"2","key":"e_1_2_1_15_2","first-page":"195","article-title":"Current proposed revision of JRA criteria","volume":"20","author":"Brewer EJ","year":"1977","journal-title":"Arthritis Rheum"},{"key":"e_1_2_1_16_2","first-page":"3","article-title":"Elaboration of the criteria for early diagnosis of juvenile rheumatoid arthritis (JRA)","volume":"4","author":"Dolgopolova AV","year":"1979","journal-title":"Questions on Rheum"},{"key":"e_1_2_1_17_2","first-page":"109","article-title":"Standard methodology for segment I, II, and III Pediatric Rheumatology Collaborative Study Group studies. I. Design","volume":"9","author":"Brewer EJ","year":"1982","journal-title":"J Rheumatol"},{"key":"e_1_2_1_18_2","first-page":"629","article-title":"Clinical trials in the rheumatic diseases","volume":"9","author":"Brewer EJ","year":"1983","journal-title":"Clin Rheum Dis"},{"key":"e_1_2_1_19_2","first-page":"114","article-title":"Standard methodology for segment I, II, and III Pediatric Rheumatology Collaborative Study Group studies. II. Analysis and presentation of data","volume":"9","author":"Giannini EJ","year":"1982","journal-title":"J Rheumatol"},{"key":"e_1_2_1_20_2","volume-title":"Biostatistical Analysis","author":"Zar JH","year":"1984"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780230403"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.1780330402","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.1780330402","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T22:44:30Z","timestamp":1700779470000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.1780330402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1990,4]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1990,4]]}},"alternative-id":["10.1002\/art.1780330402"],"URL":"https:\/\/doi.org\/10.1002\/art.1780330402","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[1990,4]]}}}